Drug General Information (ID: DDI72V51QX)
  Drug Name Rasburicase Drug Info Idelalisib Drug Info
  Drug Type Protein/peptide Small molecule
  Therapeutic Class Antihyperuricemic Agents Pi3K Inhibitors

 Mechanism of Rasburicase-Idelalisib Interaction (Severity Level: Moderate)
     Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
      Drug Name Rasburicase Idelalisib
      Mechanism Diarrhea Diarrhea
      Key Mechanism Factor 1
Factor Name Adverse reactions
Factor Description An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
      Mechanism Description
  • Increased risk of adverse reactions by the combination of Rasburicase and Idelalisib 

Recommended Action
      Management Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.

References
1 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.